ORLANDO, Fla., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. today announced that it has signed an exclusive distribution agreement with Costa Rica Based Innomedica for AVERSA Fentanyl upon approval and all sports tape products manufactured at its Pocono Pharmaceutical / Active Intell subsidiary. Innomedica will also be overseeing and financing all regulatory approvals for the above mentioned products as they ramp up for launch. About AVERSA™ Abuse-Deterrent Transdermal Technology Nutriband's AVERSA™ abu ...

Core Insights - Recent market movements have led to significant price changes for several companies, reflecting various underlying factors influencing their stock performance [1] Company Summaries - Agroz Inc. (NASDAQ:AGRZ) has seen a 37.50% drop in stock price to $2.28, with a trading volume of 988,912, indicating market skepticism or operational challenges despite launching Agroz Robotics [2] - Cresud S.A. Warrant (CRESW) experienced a 31.37% decrease in stock price to $0.7, suggesting possible market adjustments or operational issues affecting investor confidence [3] - CIMG Inc. (NASDAQ:IMG) faced a 35.08% decline in stock price to $0.12, with a 20-for-1 reverse stock split announced, reflecting potential concerns about its market position [4] - Nutriband Inc. (NASDAQ:NTRBW) saw a 42.86% decrease in stock price to $0.8, indicating regulatory challenges or market competition despite preparing for a conference presentation [5] - ScanTech AI Systems Inc. (NASDAQ:STAI) experienced a 42.79% drop in stock price to $0.21, with a delisting determination from Nasdaq contributing to its decline, highlighting challenges in the security technology sector [6] Market Dynamics - The stock market is dynamic, with companies across various sectors facing challenges that significantly impact their stock performance, influenced by operational challenges, market competition, investor sentiment, and external economic conditions [7]

Core Points - Nutriband Inc. will have its Chairman and Co-Founder, Serguei Melnik, present at NobleCon21 on December 3rd, 2025, at 9:30 AM Eastern Standard Time [1] - Interested investors can attend the conference at a discounted rate using the code NTRBNOBLECON [2] - A high-definition video webcast of the presentation will be available the following day and archived for 90 days [3] Company Overview - Nutriband Inc. focuses on developing transdermal pharmaceutical products, with its lead product being an abuse-deterrent fentanyl patch utilizing AVERSA™ technology [4] - AVERSA™ technology aims to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential [4] Noble Capital Markets - Noble Capital Markets, established in 1984, is a full-service broker-dealer providing investment and advisory services, with a strong research team and a proprietary research distribution platform [6] - Noble has raised billions of dollars for companies and published over 45,000 equity research reports [6] Channelchek - Channelchek, launched in 2018, is an investor community dedicated to emerging growth public companies, offering free institutional-quality research and advanced market data [7]

Core Insights - MediWound reported a quarterly loss of $0.24 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.81, representing an earnings surprise of +70.37% [1] - The company posted revenues of $5.43 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 15.52%, but showing an increase from $4.36 million year-over-year [2] - MediWound has surpassed consensus EPS estimates three times over the last four quarters and topped consensus revenue estimates two times in the same period [2] Financial Performance - The company experienced a loss of $0.98 per share in the same quarter last year, indicating improvement in financial performance [1] - The current consensus EPS estimate for the upcoming quarter is -$0.85 on revenues of $7.7 million, and for the current fiscal year, it is -$2.69 on revenues of $23.79 million [7] Market Position - MediWound shares have increased by approximately 0.3% since the beginning of the year, underperforming compared to the S&P 500's gain of 12.9% [3] - The Zacks Industry Rank for Medical - Drugs is in the top 29% of over 250 Zacks industries, indicating a favorable industry outlook [8] Future Outlook - The sustainability of MediWound's stock price movement will depend on management's commentary during the earnings call and future earnings expectations [3][4] - The estimate revisions trend for MediWound was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, suggesting it is expected to perform in line with the market [6]

Company Performance - TELA Bio, Inc. reported a quarterly loss of $0.19 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.17, representing an earnings surprise of -11.76% [1] - The company posted revenues of $20.69 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 5.53%, but showing an increase from $18.96 million in the same quarter last year [2] - TELA Bio has not surpassed consensus EPS estimates over the last four quarters and has topped consensus revenue estimates only once during that period [2] Stock Performance - TELA Bio shares have declined approximately 62.3% since the beginning of the year, contrasting with the S&P 500's gain of 16.5% [3] - The current Zacks Rank for TELA Bio is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is -$0.15 on revenues of $24.8 million, and for the current fiscal year, it is -$0.79 on revenues of $85.4 million [7] - The outlook for the Medical - Biomedical and Genetics industry, where TELA Bio operates, is currently in the top 35% of over 250 Zacks industries, suggesting a favorable environment for stock performance [8]

Core Insights - Korro Bio, Inc. reported a quarterly loss of $1.92 per share, which was better than the Zacks Consensus Estimate of a loss of $2.61, representing an earnings surprise of +26.44% [1] - The company generated revenues of $1.09 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 27.33%, compared to zero revenues a year ago [2] - The stock has underperformed the market, losing about 13.8% since the beginning of the year, while the S&P 500 gained 16.4% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$2.42 on revenues of $1.5 million, and for the current fiscal year, it is -$10.26 on revenues of $4.84 million [7] - The estimate revisions trend for Korro Bio, Inc. was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Drugs industry, to which Korro Bio, Inc. belongs, is currently in the top 32% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Another company in the same industry, Nutriband Inc. (NTRB), is expected to report a quarterly loss of $2.13 per share, with revenues projected at $0.68 million, reflecting a year-over-year increase of 4.6% [9]

Core Insights - Metagenomi reported a quarterly loss of $0.55 per share, which was better than the Zacks Consensus Estimate of a loss of $0.60, representing an earnings surprise of +8.33% [1] - The company generated revenues of $8.66 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 6.44% and down from $11.51 million a year ago [2] - Metagenomi shares have declined approximately 40.4% year-to-date, contrasting with the S&P 500's gain of 16.2% [3] Financial Performance - Over the last four quarters, Metagenomi has surpassed consensus EPS estimates two times [2] - The current consensus EPS estimate for the upcoming quarter is -$0.50 on revenues of $9.26 million, and for the current fiscal year, it is -$2.39 on revenues of $30.44 million [7] Market Outlook - The sustainability of Metagenomi's stock price movement will largely depend on management's commentary during the earnings call [3] - The Zacks Rank for Metagenomi is currently 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] - The Medical - Drugs industry, to which Metagenomi belongs, is currently in the top 33% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Core Insights - Ironwood Pharmaceuticals (IRWD) reported quarterly earnings of $0.24 per share, significantly exceeding the Zacks Consensus Estimate of $0.09 per share, and showing a substantial increase from $0.02 per share a year ago, resulting in an earnings surprise of +166.67% [1] - The company achieved revenues of $122.06 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 78.24% and increasing from $91.59 million year-over-year [2] - Ironwood shares have underperformed the market, losing approximately 56.7% since the beginning of the year, while the S&P 500 has gained 14.4% [3] Earnings Outlook - The future performance of Ironwood's stock will largely depend on management's commentary during the earnings call and the company's earnings outlook, including current consensus earnings expectations for upcoming quarters [4][6] - The current consensus EPS estimate for the next quarter is $0.16 on revenues of $75.53 million, and for the current fiscal year, it is also $0.16 on revenues of $270.4 million [7] Industry Context - The Medical - Drugs industry, to which Ironwood belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Another company in the same industry, Nutriband Inc. (NTRB), is expected to report a quarterly loss of $2.13 per share, reflecting a significant year-over-year decline of -1675%, with revenues projected at $0.68 million, up 4.6% from the previous year [9]

Core Insights - Nutriband has initiated the development of a worldwide brand name for its lead product, an abuse-deterrent fentanyl transdermal system, in partnership with Brand Institute, Inc [1][10] - The AVERSA™ FENTANYL product aims to be the first abuse-deterrent opioid patch, designed to prevent misuse and accidental exposure to fentanyl [2][6] Company Overview - Nutriband is focused on developing transdermal pharmaceutical products, with its lead product being an abuse-deterrent fentanyl patch utilizing AVERSA™ technology [8] - The AVERSA™ technology incorporates aversive agents into transdermal patches to mitigate the risks of abuse and accidental exposure [6][7] Brand Development - Developing a proprietary brand name is crucial for distinguishing the product from similar-sounding or looking drug names, which can prevent medication errors [3] - Brand Institute holds a significant market share, with a 75% approval rate for drug names globally, including 87% of FDA-approved names in 2024 [4][10] Regulatory Support - Drug Safety Institute, a subsidiary of Brand Institute, will provide regulatory services for the project, staffed by former officials from major health agencies [5][10] - The expertise of Drug Safety Institute includes co-authoring naming guidance documents, ensuring safety and preventing medication errors [5][10]

Key Points - Several biotech stocks experienced notable after-hours gains on October 9, driven by new data and corporate developments [1] Company Summaries Palisade Bio Inc. (PALI) - Shares traded at $2.26 in after-hours, reflecting a 7.62% gain from the prior close of $2.10, which was up 5% on the day [1] - The company cancelled its special meeting of stockholders due to lack of quorum, withdrawing all proposals from consideration [2] Healthcare Triangle Inc. (HCTI) - Shares traded at $2.88 in after-hours, up 4.35% from the regular session close of $2.76, which was down 17.86% [3] - The company signed a non-binding Letter of Intent to acquire Teyame.AI, projected to generate $34 million in revenue for fiscal year 2025 [4] Nutriband Inc. (NTRB) - Shares traded at $8.25 in after-hours, up 4.30% from the regular session close of $7.91, which was down 6.94% [5] - The company filed a provisional patent application with the USPTO to strengthen its intellectual property for its AVERSA abuse deterrent transdermal [5] Karyopharm Therapeutics Inc. (KPTI) - Shares traded at $6.08 in after-hours, up 4.46% from the regular session close of $5.82, which had declined 1.36% [6] - The company announced financing transactions expected to provide $100 million in financial flexibility, extending its cash runway into Q2 2026 [6] Editas Medicine Inc. (EDIT) - Shares traded at $4.22 in after-hours, up 3.43% from the regular session close of $4.08, which was down 1.69% [7] - The company presented new preclinical proof-of-concept data for its therapy EDIT-401, showing a 90% LDL-C reduction in non-human primates and mice [7] CG Oncology Inc. (CGON) - Shares traded at $45.40 in after-hours, up 2.11% from the regular session close of $44.46, which gained 9.21% [8] - No official news releases or filings were issued during the day [8]